Given the ability to control both tumor cell division and hormone secretion through the somatostatin receptor, the development of somatostatin analogs has become a key target in non-surgical therapy and is the fundamental principal behind Lutetium-177-Dotatate therapy (Love et al. 2022). The gene discussed is SST; the disease is neoplasm.